Basics Aclaris Therapeutics, Inc. Aclaris Therapeutics Inc is a clinical-stage specialty pharmaceutical company which focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology. IPO Date: October 7, 2015 Sector: Healthcare Industry: Biotech Market Cap: $164.59M Activated in VL: True Average Daily Range Avg Daily Range: $0.35 | 3.17% Avg Daily Range (30 D): $0.04 | 2.52% Avg Daily Range (90 D): $0.04 | 3.10% Institutional Daily Volume Avg Daily Volume: .67M Avg Daily Volume (30 D): .66M Avg Daily Volume (90 D): .73M Trade Size Avg Trade Size (Sh.): 151 Avg Trade Size (Sh.) (30 D): 158 Avg Trade Size (Sh.) (90 D): 164 Institutional Trades Total Inst.Trades: 1,174 Avg Inst. Trade: $1.57M Avg Inst. Trade (30 D): $4.47M Avg Inst. Trade (90 D): $3.34M Avg Inst. Trade Volume: .14M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.5M Avg Closing Trade (30 D): $10.84M Avg Closing Trade (90 D): $6.68M Avg Closing Volume: 142.04K     News May 9, 2025 @ 11:00 AM Aclaris Therapeutics to Participate in the HC Wain... Source: N/A Apr 29, 2025 @ 11:00 AM Aclaris Therapeutics Appoints Jesse Hall, M.D. as ... Source: N/A Mar 3, 2025 @ 6:00 PM JAK Inhibitors Clinical Trial Pipeline Appears Rob... Source: Delveinsight Sep 10, 2024 @ 11:00 AM Aclaris Therapeutics to Participate in the 2024 Ca... Source: N/A Jul 23, 2024 @ 11:31 AM Aclaris Therapeutics And 3 Other Stocks Under $2 I... Source: Avi Kapoor Financials   TTM Q1 2025 Q4 2024 Basic EPS $-1.59 $-.12 $-1.21 Diluted EPS $-1.59 $-.12 $-1.21 Revenue $ 17.78M $ 1.46M $ 9.21M Gross Profit $ 15.29M $ .95M $ 8.51M Net Income / Loss $ -130.21M $ -15.09M $ -96.55M Operating Income / Loss $ -141.09M $ -18.08M $ -99.68M Cost of Revenue $ 2.49M $ .51M $ .71M Net Cash Flow $ -5.48M $ 5.79M $ -23.08M PE Ratio